Inactive Instrument

Mitsubishi Tanabe Pharma Corporation

Equities

4508

JP3469000008

Mitsubishi Tanabe Pharma Corporation Revises Earnings Guidance for the Year 2020

November 19, 2018 at 12:00 am

Mitsubishi Tanabe Pharma Corporation revised earnings guidance for the year 2020. For the year, the company now expects revenue of JYP 430.0 billion against previous guidance of JPY 500.0 billion and core operating profit of JPY 60.0 billion against previous guidance of JPY 100.0 billion.

Latest news about Mitsubishi Tanabe Pharma Corporation

Grand Pharmaceutical Co., Ltd. entered into an equity acquisition agreement to acquire 75.35% stake in Tianjin Tanabe Seiyaku Co. Ltd. from Mitsubishi Tanabe Pharma Corporation for approximately HKD 400 million.	12-20	CI
Certain Options of NewAmsterdam Pharma Company N.V. are subject to a Lock-Up Agreement Ending on 4-SEP-2023.	23-09-03	CI
Certain Warrants of NewAmsterdam Pharma Company N.V. are subject to a Lock-Up Agreement Ending on 4-SEP-2023.	23-09-03	CI
Certain Common Stock of NewAmsterdam Pharma Company N.V. are subject to a Lock-Up Agreement Ending on 4-SEP-2023.	23-09-03	CI
Mitsubishi Tanabe Pharma America Presents 48-Week Results from Global Phase 3 Safety Clinical Study of Radicava Ors®, an Oral Treatment for Als	22-06-01	CI
Mitsubishi Tanabe Pharma Corporation Announces Regulatory Approval of Dysval® (Valbenazine) for the Treatment of Tardive Dyskinesia in Japan	22-03-28	CI
Mitsubishi Tanabe Pharma America Presents REFINE-ALS Biomarker Study Details At Virtual 32nd International Symposium on ALS/MND	21-12-10	CI
Mitsubishi Tanabe Pharma Corporation Reports Earnings Results for the First Quarter Ended June 30, 2021	21-08-04	CI
Mitsubishi Tanabe Pharma America Announces EXSERVAN™ is Now Available in the U.S. for the Treatment of ALS	21-06-30	CI
Mitsubishi Tanabe Pharma Corporation Presents Data on Impact of ALS Symptoms on Patients' Ability to Independently Conduct Daily Activities	21-03-17	CI
Transcript : Mitsubishi Tanabe Pharma Corporation - Special Call	21-03-02
Pharma Foods International Co., Ltd. Enters into Exclusive Licensing Agreement with Mitsubishi Tanabe Pharma Corporation for A New Therapeutic Antibody to Treat Autoimmune Diseases	21-01-26	CI
Mitsubishi Tanabe Pharma Corporation Announces Board Changes	20-02-25	CI
Transcript : Mitsubishi Tanabe Pharma Corporation, Q3 2020 Earnings Call, Feb 04, 2020	20-02-04
Mitsubishi Tanabe Pharma Corporation Reports Consolidated Earnings Results for the Nine Months Ended December 31, 2019; Provides Earnings Guidance for the Year Ending March 31, 2020; Provides Dividend Guidance for the Year Ending March 31, 2020	20-02-04	CI
Nipro Pharma Corporation cancelled the acquisition of Tanabe Seiyaku Yoshiki Factory Co., Ltd. from Mitsubishi Tanabe Pharma Corporation.	20-01-30	CI
Mitsubishi Tanabe Pharma Corporation(TSE:4508) dropped from S&P Japan 500	20-01-20	CI
Mitsubishi Tanabe Pharma Corporation(TSE:4508) dropped from S&P Japan Mid Cap 100	20-01-20	CI
Mitsubishi Tanabe Pharma Corporation(TSE:4508) dropped from S&P Global BMI Index	20-01-20	CI
Mitsubishi Tanabe Pharma Corporation Announces Executive Changes, Effective April 1, 2020	20-01-14	CI
Mitsubishi Tanabe Pharma Corporation(TSE:4508) dropped from FTSE All-World Index	20-01-13	CI
Mitsubishi Chemical Holdings Corporation completed the acquisition of 35.18 % stake in Mitsubishi Tanabe Pharma Corporation.	20-01-06	CI
Mitsubishi Chemical : Chem to spend $4.5 billion to buy rest of Tanabe	19-11-18	RE
Mitsubishi Chemical Holdings Corporation made an offer to acquire remaining 43.61% stake in Mitsubishi Tanabe Pharma Corporation for approximately ¥490 billion.	19-11-17	CI
Biotech-for-hire PeptiDream charts new path and becomes short target	19-11-13	RE

Chart Mitsubishi Tanabe Pharma Corporation

Duration

Period

Chart Mitsubishi Tanabe Pharma Corporation

More charts

Company Profile

Mitsubishi Tanabe Pharma Corporation is a Japan-based company mainly engaged in the manufacture and sale of pharmaceutical products. The medical supplies business is engaged in the research, development, manufacture and sale of ethical pharmaceutical and non-prescription drugs. The Company's subsidiaries receive raw materials from the company and sell products locally.

Sector

More about the company